Pilot study of epigenetic aging and treatment response to semaglutide in the SLIM LIVER study.

npj aging

The effects of GLP-1 receptor agonists on Alzheimer's pathophysiology: A systematic review.

Molecular and cellular neurosciences

Cost-Effectiveness of Incretin Therapies: A Canadian Lens on Diabetes, Obesity, and Emerging Indications.

Canadian journal of physiology and pharmacology

Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.

Journal of medical economics

Integrated Evidence from VigiBase and Clinical Trials: A Comprehensive Pharmacovigilance Analysis of Seven Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs).

Diabetes therapy : research, treatment and education of diabetes and related disorders

Rapid remission of Hailey-Hailey disease with tirzepatide therapy: A case report.

JAAD case reports

Dynamics of Body Composition and Metabolic Risk in Adolescents With Obesity Under GLP-1 Receptor Agonist Therapy.

Acta paediatrica (Oslo, Norway : 1992)

A novel, widespread impurity in mass-compounded tirzepatide/b12 products: patient safety implications.

Expert opinion on drug safety

BEST PEPTIDES: S-Tier: Tirzepatide, Tesamorelin, Oxytocin A-Tier: Semaglutide, Sermorelin, Melanotan 1 B-Tier: NAD+ C-Tier: Everything else due to purity issues, until they can be legally compounded by US pharmacies (e.g. Retatrutide, BPC-157, TB-4, CJC, MT2, MOTS-c, etc.)

SKIP HYPE: If you want to HEAL faster, Skip BPC-157 (poor data) Take a Growth Hormone peptide (TESAMORELIN) If you want to lose FAT, Skip Reta (stimulates the heart) Take a GLP-1/GIP (TIRZEPATIDE) If you want to feel CALM, Skip Selank (poor data) Take a neuropeptide (OXYTOCIN)

@TheLongInvest For now, it's $HIMS. But I suspect it'll be $AVCT #AVCT in the not-too-distant future. The large majority of US retail associate #peptides with the GLP-1 mimetics (semaglutide, tirzepatide) and bioregulatory / research peptides (e.g. BPC-157; TB-500; GHK-Cu, etc.). But the

Amazon just launched a GLP-1 program through One Medical. $149/mo oral. $299/mo injectable. But GLP-1s are one peptide class out of dozens. BPC-157, Thymosin Beta-4, GHK-Cu, MOTS-c... the real wave hasn't even started. The FDA is deregulating 12+ peptides. Amazon is entering https://t.co/NqBTc9WhHt

🚨 $HIMS +46% in 1 week as FDA schedules peptide compounding review (July 23–24) The FDA will evaluate 7 peptides for compounding eligibility: → BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon ✅Hims & Hers CMO called it an “avenue toward trusted channels” This is https://t.co/yKIFM6lEZh

Did a bit of research and seems like these are most used peptides: -tirzepatide -semaglutide -BPC-157 -TB-500 -ipamorelin What do you think of peptides?

🚨 $KITL BULLISH ALERT: FDA Peptide Reversal = Massive Catalyst for the OTC Pioneer! With RFK Jr. at HHS and the FDA now actively weighing the lift on restrictions for ~14 key peptides (BPC-157, TB-500, CJC-1295, GHK-Cu, and more), the gray-market peptide era is ending — and

• HHS Secretary Kennedy just announced the FDA is removing 12 key peptides from Category 2 restrictions starting with BPC-157 and others moving to full scientific review. • $HIMS is not a GLP-1 only company. The entire peptide industry stands ready to boom as regulated access https://t.co/3HzcTJWfS0 https://t.co/9UySm2FWBU